Morgan Stanley Lowers Omada Health (NASDAQ:OMDA) Price Target to $30.00

Omada Health (NASDAQ:OMDA) had its price target dropped by analysts at Morgan Stanley from $32.00 to $30.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 113.52% from the company’s current price.

Several other equities analysts also recently commented on OMDA. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of Omada Health in a research note on Thursday, January 22nd. Evercore boosted their price objective on shares of Omada Health from $27.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, November 7th. The Goldman Sachs Group restated a “buy” rating and set a $26.00 target price on shares of Omada Health in a research report on Friday, January 16th. Wells Fargo & Company started coverage on shares of Omada Health in a report on Thursday, January 8th. They set an “equal weight” rating and a $17.00 target price on the stock. Finally, BMO Capital Markets started coverage on Omada Health in a research note on Thursday, November 13th. They issued an “outperform” rating and a $27.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $22.90.

Omada Health Trading Up 3.3%

Shares of NASDAQ OMDA opened at $14.05 on Friday. The firm has a market cap of $813.61 million and a P/E ratio of -56.20. The business’s 50 day moving average is $14.03 and its 200-day moving average is $18.67. Omada Health has a 1-year low of $10.28 and a 1-year high of $28.40.

Omada Health (NASDAQ:OMDA) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.12. The firm had revenue of $75.85 million during the quarter.

Insider Activity

In other Omada Health news, CEO Sean P. Duffy sold 40,796 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $15.95, for a total transaction of $650,696.20. Following the sale, the chief executive officer directly owned 126,644 shares in the company, valued at $2,019,971.80. This represents a 24.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, President Wei-Li Shao sold 5,618 shares of the firm’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $16.13, for a total transaction of $90,618.34. Following the completion of the transaction, the president directly owned 69,079 shares in the company, valued at approximately $1,114,244.27. This represents a 7.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 276,893 shares of company stock valued at $4,336,787 in the last ninety days.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Strs Ohio acquired a new position in Omada Health during the third quarter valued at approximately $38,000. Raymond James Financial Inc. bought a new position in shares of Omada Health in the 2nd quarter valued at $32,000. Quarry LP bought a new position in shares of Omada Health in the 4th quarter valued at $29,000. TD Waterhouse Canada Inc. acquired a new position in shares of Omada Health during the 4th quarter worth $32,000. Finally, Rakuten Investment Management Inc. bought a new stake in shares of Omada Health during the 3rd quarter worth $49,000.

Omada Health News Roundup

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Q4 results beat consensus — Omada reported $0.08 EPS vs. a ($0.04) consensus and $75.85M revenue, with year-over-year revenue growth and positive adjusted EBITDA and Q4 net income, signaling improving profitability. GlobeNewswire: Q4 & Full-Year Results
• Positive Sentiment: Company set a 2026 revenue-growth target (~22%) and is expanding its care offerings (new GLP-1 and cholesterol programs), which underpin upside to recurring revenue and member monetization. Seeking Alpha: 22% Growth Target & New Programs
• Positive Sentiment: Product launch — Omada announced “GLP‑1 Flex Care,” a program that enables employer-sponsored access to GLP‑1 obesity care while limiting employer drug-cost exposure, which could broaden sales channels and employer uptake. GlobeNewswire: GLP-1 Flex Care
• Positive Sentiment: Goldman Sachs maintained a Buy rating with a $26 target, citing a profitability inflection and double-digit growth outlook — a supportive institutional endorsement. TipRanks: Goldman Sachs Note
• Neutral Sentiment: Morgan Stanley trimmed its price target slightly (from $32 to $30) but kept an Overweight rating — still implies significant upside, so the impact is muted. Benzinga: Morgan Stanley PT
• Negative Sentiment: Several firms cut price targets — Canaccord lowered its target to $22 (still Buy), BMO cut to $18 (Outperform), and Barclays reduced its target to $17 — these cuts can create downward pressure despite bullish ratings. Benzinga: Canaccord / BMO notes TickerReport AmericanBankingNews: Barclays

About Omada Health

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.